179 related articles for article (PubMed ID: 27783399)
1. Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
; Adamo MP; Boten JA; Coyle LM; Cronin KA; Lam CJ; Negoita S; Penberthy L; Stevens JL; Ward KC
Cancer; 2017 Feb; 123(4):697-703. PubMed ID: 27783399
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
[TBL] [Abstract][Full Text] [Related]
3. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer.
Xiao WJ; Zhu Y; Zhu Y; Dai B; Ye DW
World J Urol; 2018 May; 36(5):769-774. PubMed ID: 29372356
[TBL] [Abstract][Full Text] [Related]
5. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
[TBL] [Abstract][Full Text] [Related]
7. Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database.
Daugherty M; Sedaghatpour D; Bratslavsky G; Shapiro O
Can J Urol; 2018 Aug; 25(4):9414-9420. PubMed ID: 30125522
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.
Schymura MJ; Sun L; Percy-Laurry A
Cancer; 2014 Dec; 120 Suppl 23():3758-70. PubMed ID: 25412388
[TBL] [Abstract][Full Text] [Related]
9. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
10. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
[TBL] [Abstract][Full Text] [Related]
11. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
Scosyrev E; Wu G; Mohile S; Messing EM
Cancer; 2012 Dec; 118(23):5768-76. PubMed ID: 22847578
[TBL] [Abstract][Full Text] [Related]
14. Value of prostate-specific antigen in the staging of Taiwanese patients with newly diagnosed prostate cancer.
Meng E; Sun GH; Wu ST; Chuang FP; Lee SS; Yu DS; Yen CY; Chen HI; Chang SY
Arch Androl; 2003; 49(6):471-4. PubMed ID: 14555332
[TBL] [Abstract][Full Text] [Related]
15. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
16. US National Cancer Institute investigates PSA coding errors.
Furlow B
Lancet Oncol; 2015 Jun; 16(6):614. PubMed ID: 25936986
[No Abstract] [Full Text] [Related]
17. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
Terakedis BE; Rossi PJ; Liauw SL; Johnstone PA; Jani AB
Am J Clin Oncol; 2010 Dec; 33(6):619-23. PubMed ID: 20051808
[TBL] [Abstract][Full Text] [Related]
20. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
